Sector revisions Lupin Limited

Equities

Market Closed - Bombay S.E. Other stock markets 11:00:56 05/06/2026 BST			5-day change	1st Jan Change
2,268.10 ^INR	+0.86%		-0.19%	+7.39%

06-05	Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments	MT
06-04	Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	LUPIN LIMITED							38
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							23
	ABBVIE INC.							29
	ROCHE HOLDING AG							17
	MERCK & CO., INC.							27
	ASTRAZENECA PLC							21
	NOVARTIS AG							21
	NOVO NORDISK A/S							23
	AMGEN INC.							30
	GILEAD SCIENCES, INC.							29
	PFIZER INC.							27
	BRISTOL-MYERS SQUIBB COMPANY							25
	VERTEX PHARMACEUTICALS INCORPORATED							29
	SANOFI							23
	GSK PLC							20
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							16
	Average							24
	Weighted average by Cap.							25